UK: Beyond Pharma: The Role Of Medtech In Antimicrobial Resistance

Last Updated: 8 January 2019
Article by Paul Chapman

A major review published by the World Health Organisation threw the spotlight once again on the issue of antimicrobial resistance (AMR) and the ongoing misuse of antibiotics around the world.

Despite heightened public awareness of the challenge and potentially disastrous consequences of AMR, the WHO's latest report reveals that much remains to be done with drastic overuse of antibiotics still a reality in many countries around the world. In 49 of the countries surveyed by the WHO, for example, it was found that antibiotics meant to be held in reserve for when first and second resort drugs fail, accounted for half of all prescribing.

Mongolia was found to have the highest level of prescribing globally, with 64.4 doses issued per every 1000 people, followed by Iran and Turkey with 38.8 and 38.2 doses respectively. No matter which countries are the worst or best behaved when it comes to using antibiotics appropriately, however, the global movement of people and goods ensures that AMR is a challenge for all of us.

Beyond pharma

While novel pharmaceuticals are vital when mitigating the effects of ever-evolving pathogens, they are not the only solution. Often what is driving over-prescription of antibiotics in countries such as those named in the WHO report, is not a wilful decision to use antibiotics unnecessarily, but rather risk aversion.

If a patient presents with symptoms that could equally be those of a common cold or a serious bacterial infection, and there's no clear way of being sure which is the correct diagnosis, then most of us would likely opt to prescribe antibiotics, rather than risk the patients' health. This is where better diagnostic technology becomes a significant tool in fighting AMR.

If technology can be developed that allows clinicians in rural Mongolia and elsewhere to diagnose patients quickly and accurately, as well as make the distinction between bacterial infection and less serious complaints, then this will go a long way towards stemming over-prescription.

Medtech

Like the pharmaceutical industry, the medical devices and technology (medtech) industry has also been responding to the AMR challenge. At Marks & Clerk, we recently worked with Nesta – the innovation foundation – on a  report looking at the levels of innovation geared towards AMR in the medtech industry.

Our findings give some cause for hope, but also reveal that there is some way to go if medtech is to make a meaningful contribution to stopping the over-prescription of antibiotics. While, for example, we have seen a generally upward trend in patent filing in the field of point-of-care (POC) diagnostic devices over the past 10 years, this has in recent years plateaued and perhaps gone into reverse.

There is a significant lag between a patent being filed, and it showing on any patent register, so some of the decline we have seen will be attributable to that lag. Nevertheless, the lag is unlikely to account for all of this decline, and if this trend continues into coming years it should serve to focus minds further on the challenge of AMR.

Prioritising pathogens

Despite the decline in patent filings we've seen aimed at POC diagnostics in recent years, the filings we have seen have been more focused on better bacterial diagnostics.

Analysis of patent filings reveals that, of the 374 patent applications indicating the pathogen type, the majority relate to detection of bacterial infection, with around a third relating to detection of viral infection, and a minority relating to fungal or parasitic infections.

Interestingly, although the relative numbers of patent filings have decreased in the last five years, the percentage relating to the detection of bacteria has increased over recent years from 51% to 81%.

This may point to increasing awareness of antibiotic resistance and misuse, and the importance of detecting bacteria correctly. Correctly detecting whether an infection is bacterial or viral in origin will undoubtedly reduce inappropriate use of antibiotics, and identifying a particular bacterial species and susceptibility of antibiotics will enable the correct narrow-spectrum antibiotic to be chosen.

Antibiotics can be split generally into two separate camps: broad spectrum antibiotics, which work on a wide range of bacteria, and narrow-spectrum antibiotics developed for a specific bacterial infection. Prescribing broad-spectrum antibiotics is linked to the increased development of AMR and increases personal risk through the destruction of the body's natural non-pathogenic bacteria. Thus, there is a significant role for narrow-spectrum, more specific antibiotics and diagnostic tests, which are able to specifically identify particular microorganisms.

Minds also seem to have been focused in the medtech world – as they no doubt have been in the pharmaceutical world – by the WHO's publication of a list of 12 'priority pathogens'. These are the 12 pathogens determined by the WHO to pose the greatest risk to human health and some of which exhibit resistance to multiple antibiotics. While it is too soon after the WHO publication to see any resultant filing activity, the percentage of applications specifically mentioning the types of bacteria in the WHO list appears to have reduced dramatically in the last five years. However, despite this decline, the percentage of filings relating to the detection of bacteria has increased.

Challenging innovation

It's clear that, alongside novel pharmaceuticals, better POC diagnostic devices have a significant role to play in stopping the emergence of antibiotic-resistant bacteria.

As with pharmaceuticals, however, the market for medtech devices aimed at AMR is frustrated by the nature of the problem. Just as there is an illogic to investing huge sums of money in the development of antibiotics which, to remain effective, must be used sparingly and so have a limited market, so too the medtech device which can be easily deployed globally to allow better diagnosis would necessarily have to be affordable, therefore limiting potential returns. So, while willingness and the technical capability are plentiful, investment is sometimes less so.

The nature of AMR, and the inversion of normal economics that its solution demands, will continue to challenge innovation in this area. Solutions must be found, however, to avoid returning to what many claim would be the medical 'dark ages' if our antibiotics are rendered ineffective by overuse.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Topics
 
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions